Renal Denervation

SYMPLICITY HTN-3 TRial, ACC.14, renal denervation

A major disappointment earlier this year was the announcement by Medtronic that its renal denervation system failed to meet its primary endpoint for efficacy in the U.S. SYMPLICITY HTN-3 trial. This trial data was presented to a packed, standing-r...

Results from several late breaking clinical trials will be presented during  the American College of Cardiology (ACC) 2014 annual meeting March 29-31. These wil...

Medtronic Inc. announced its U.S. pivotal trial for its Symplicity renal denervation system to treat resistant hypertension, the SYMPLICITY HTN-3 trial, failed to meet its primary efficacy endpoint. The trial met its primary safety endpoint, and t...

Medtronic Inc. announced CE mark in Europe and Therapeutic Goods Administration (TGA) listing in Australia for its flexible 4 French multi-electrode Symplicity Spyral cath...

Medtronic, SYMPLICITY, SYMPLICITY HTN-3 trial, renal denervation, ACC.14
A major disappointment earlier this year was the announcement by Medtronic that its renal denervation system failed to meet its primary endpoint for efficacy...
CBSET Renal Denervation Hypertension Therapies Symplicity-3 Trial
Scientists at CBSET are reminding thought leaders in renal denervation that there is a seminal experimental and computational template for the more rational,...
American College of Cardiology Clinical Trial Cath Lab EP Cardiac Diagnostics
Results from several late breaking clinical trials will be presented during  the American College of Cardiology (ACC) 2014 annual meeting March...
ReCor Medical Paradise System Renal Denervation RDN Therapy Hypertension
ReCor Medical advanced its Paradise System for renal denervation (RDN) for treatment resistant hypertension (HTN).

Articles

Medtronic, SYMPLICITY, SYMPLICITY HTN-3 trial, renal denervation, ACC.14
A major disappointment earlier this year was the announcement by Medtronic that its renal denervation system failed to meet its primary endpoint for efficacy...
Medtronic, symplicity, renal denervation
Medtronic Inc. announced its U.S. pivotal trial for its Symplicity renal denervation system to treat resistant hypertension, the SYMPLICITY HTN-3 trial, failed...
acc pharmaceuticals renal denervation heart valve repair antiplatelet therapy
Clinical trials for a promising new class of cholesterol-lowering medications, a long-awaited repair of the Medicare formula for paying physicians, the...
medtronic symplicity spyral renal denervation cath lab hypertension treatment G3
Medtronic Inc. announced CE mark in Europe and Therapeutic Goods Administration (TGA) listing in Australia for its flexible 4 French multi-electrode Symplicity...

Video Center

By Dave Fornell The biggest news item from the American College of Cardiology (ACC) 63rd Annual...
1 week 20 hours ago
By Dave Fornell, DAIC editor Data from several cutting-edge device clinical trials will be...
3 weeks 21 hours ago
By Dave Fornell, editor I have watched a trend in medical technology grow from a small ripple a...
4 weeks 16 hours ago
The webinar "PET/CT: A New Frontier" discusses potential benefits of digital relative to analog PET/CT. The session will discuss how digital PET can improve image quality, lesion detection and...
CVIS, cardiovascular information system
This webinar reviews multi-ology, multi-site, vendor neutral solutions that transform rigid departmental information silos into fluid, consolidated, information sharing systems. It discusses how to...
Centricity Cardio Enterprise, Cardiac PACS, Cardio PACS, CVIS
February is American Heart Month, the perfect time to evaluate the health of your cardiology IT system. 
Join us Feb. 25, 2-3 p.m. Eastern for a live demonstration on Centricity Cardio Enterprise...

Comparison Charts

Sorry there is no data available